Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI's) lamivudine [(-)2'-deoxy-3'thiacytidine, 3tc], zidovudine (ZDV) and 1592U89 [abacavir]

Trial Profile

A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI's) lamivudine [(-)2'-deoxy-3'thiacytidine, 3tc], zidovudine (ZDV) and 1592U89 [abacavir]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelfinavir (Primary) ; Abacavir; Lamivudine; Zidovudine
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PENTA-5
  • Most Recent Events

    • 23 Jul 2009 Actual end date (31 Jul 1999) added as reported by ISRCTN: Current Controlled Trials.
    • 23 Jul 2009 Additional lead trial centres, planned patient number (120) and actual initiation date (23 Jan 1998) added as reported by ISRCTN: Current Controlled Trials.
    • 23 Jul 2009 Planned patient number (120) added as reported by ISRCTN: Current Controlled Trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top